Skip to main content
Kamada Ltd. logo

Kamada Ltd. — Investor Relations & Filings

Ticker · KMDA ISIN · IL0010941198 TA Manufacturing
Open in API
Filings indexed 824 across all filing types
Latest filing 2025-10-23 Report Publication Anno…
Country IL Israel
Listing TA KMDA

About Kamada Ltd.

https://www.kamada.com

Kamada Ltd. is a vertically integrated global biopharmaceutical company specializing in plasma-derived protein therapeutics. The company develops, manufactures, and commercializes a portfolio of products for rare and serious conditions, with a focus on therapeutic areas such as Alpha-1 Antitrypsin Deficiency (AATD) and Cytomegalovirus (CMV) prevention in transplant patients. Kamada utilizes a proprietary platform technology for advanced protein extraction and purification from human plasma. In addition to its marketed products, the company maintains a development pipeline of new therapies, including an inhaled treatment for AATD.

Recent filings

Filing Released Lang Actions
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 10, 2025, PROXY STATEMENT
Report Publication Announcement Classification · 1% confidence The document is a short regulatory filing (1809 characters) that explicitly states 'Attached hereto is a report on NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS' and provides a filename for the attachment. According to the 'Menu vs Meal' rule, a document that announces the publication or attachment of another report is classified as a Report Publication Announcement (RPA).
2025-10-23 English
Kamada to Participate in Upcoming September Investor Conferences
Regulatory Filings Classification · 1% confidence The document is a Form 6-K filed with the SEC by Kamada Ltd. The content of the filing is an announcement regarding the company's participation in upcoming investor conferences. While it contains information about the company, it is primarily a regulatory filing used to disseminate a press release about management's schedule and investor relations activities. Since it does not fit into specific categories like 'Investor Presentation' (which would be the slides themselves) or 'Earnings Release', and it is a standard regulatory disclosure of a press release, 'RNS' (Regulatory Filings) is the most appropriate classification.
2025-09-02 English
Kamada to Participate in Upcoming September Investor Conferences
Regulatory Filings Classification · 1% confidence The document is a short notification from Kamada Ltd announcing their participation in upcoming investor conferences. It explicitly states 'Attached hereto is a report on Kamada to Participate in Upcoming September Investor Conferences' and provides a file reference. Following the 'Menu vs Meal' rule, since this is a short announcement regarding the publication/availability of an attached document, it is classified as a Report Publication Announcement (RPA).
2025-09-02 English
Second Quarter and First Half 2025 Financial Results
Earnings Release Classification · 1% confidence The document is a Form 6-K filed with the U.S. Securities and Exchange Commission by Kamada Ltd. It contains an earnings release (Exhibit 99.1) detailing financial results for the second quarter and first half of 2025, along with an investor presentation and financial statements. While it includes an earnings release, the document itself is a formal regulatory filing (Form 6-K) used to transmit these materials to the SEC. According to the filing definitions, Form 6-K is a standard regulatory filing for foreign private issuers. Q2 2025
2025-08-13 English
Second Quarter and First Half 2025 Financial Results
Earnings Release Classification · 1% confidence The document is a short notification from Kamada Ltd to the Israel Securities Authority regarding the publication of their financial results. It explicitly states 'Attached hereto is a report on...' and provides a filename for the actual financial report. Following the 'Menu vs Meal' rule, since this is a short announcement (2139 characters) notifying the public that a report has been published, it is classified as a Report Publication Announcement (RPA). H1 2025
2025-08-13 English
FDA Approval of its Plasma Collection Center in Houston, Texas
Regulatory Filings Classification · 1% confidence The document is a Form 6-K filed with the U.S. Securities and Exchange Commission by Kamada Ltd. Form 6-K is a standard regulatory filing used by foreign private issuers to report material events. The content of this specific filing is an announcement regarding FDA approval of a plasma collection center. Since it is a general regulatory filing that does not fit into more specific categories like 'Earnings Release' or 'Annual Report', it is classified as a Regulatory Filing (RNS).
2025-08-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.